The global EYLEA drug market comprises drugs used for the treatment of different retinal disorders. EYLEA, developed by Regeneron Pharmaceuticals and Bayer, is a vascular endothelial growth factor inhibitor used for the treatment of wet age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. The drug inhibits abnormal growth of new blood vessels and leakage that can lead to vision loss. EYLEA has advantages over other drugs as it provides long-lasting control of retinal disorders with fewer injections required. With rising cases of retinal disorders due to increasing geriatric population and growing prevalence of diabetes and hypertension, the need for effective retinal disorder treatment drugs is rising globally.
The Global EYLEA Drug Market Size is estimated to be valued at US$ 8.79 Bn in 2024 and is expected to exhibit a CAGR of 7.2% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the global EYLEA drug market are Bayer, Regeneron Pharmaceuticals, Coherus BioSciences, Inc., and Klinge Biopharma. Regeneron Pharmaceuticals and Bayer currently dominate the market with their EYLEA drug which has significantly contributed to market growth over the past few years.
The global EYLEA drug market is witnessing high growth owing to the rising prevalence of retinal disorders among the geriatric population across major markets. Growing diabetes and hypertension patient bases have also raised cases of related retinal disorders such as diabetic retinopathy and macular edema, thereby driving demand for effective treatment options like EYLEA drugs.
Major pharmaceutical players are also expanding their EYLEA drug manufacturing and distribution networks globally. Companies are focusing on obtaining regulatory approvals in high potential markets and emerging regions to further penetrate the global market. Partnerships with local pharma players are also helping companies expand in regional EYLEA drug markets.
Market Drivers
Rising geriatric population prone to retinal disorders: Population aging is a key driver as retinal disorders are more common among the elderly. With over 1 billion geriatric population expected worldwide by 2050, the retinal disorder patient pool is set to surge tremendously.
Increasing cases of diabetes: Diabetes is a leading cause of vision loss and retinal disorders as it can damage tiny blood vessels inside the retina. With global diabetes prevalence having doubled since 1980, retinal disorder incidence fueled by diabetes has also increased substantially.
Lack of effective substitutes: EYLEA faces minimal competition from other drugs as alternatives provide relatively shorter efficacy or require frequent injections. This leaves EYLEA as the most effective long-term option for treating retinal disorders currently.
The current geopolitical situation has significantly impacted the growth of the Global EYLEA Drug market. Many countries are witnessing political unrest, conflicts and tensions which has disrupted cross-border trade and supply chains. This has led to delays in supply of key materials and raw materials which are essential for manufacturing EYLEA drugs. It has also disrupted trade relationships and partnerships which companies relied upon for sales and distribution of their products in global markets.
Going forward, companies operating in this market need to diversify their supplier base and look at alternative sourcing options from politically more stable regions. They also need to decentralize manufacturing capacities across multiple countries and regions to mitigate risks from any future supply disruptions. Establishing localized manufacturing and distribution networks in different geographies will help insulate them from geopolitical issues and enable sustained supply even during times of conflicts or trade tensions. Companies also need to explore opportunities in fast growing markets which offer stability and growth prospects despite global uncertainties.
The United States is currently the largest market for EYLEA drugs in terms of value. Its well-established healthcare system, large patient population and higher affordability levels have contributed to its dominant position. Europe is also among the major revenue generators owing to supportive government initiatives and public health insurance coverage across many countries.
However, the Asia Pacific region excluding Japan is emerging as the fastest growing market for EYLEA drugs. Countries like China, India, South Korea and others are witnessing rising income levels, growing medical tourism and increasing prioritization of healthcare spending which is driving strong demand growth. Rapid infrastructure development, healthcare reforms and expanding insurance coverage are some factors fueling the market in this high potential region.
What Are The Key Data Covered In This Global EYLEA Drug Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Global EYLEA Drug Market’s growth between 2024 and 2031.
:- Accurate calculation of the size of the Global EYLEA Drug Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Global EYLEA Drug Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Global EYLEA Drug Market vendors
FAQ’S
Q.1 What are the main factors influencing the Global EYLEA Drug market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Global EYLEA Drug Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Global EYLEA Drug market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
Get more insights on this topic: https://dailygram.com/blog/1296467/global-eylea-drug-market-will-grow-at-highest-pace-owing-to-increasing-prev/